CRISPR Therapeutics AG (CRSP)
53.74
-1.91
(-3.43%)
USD |
NASDAQ |
Apr 25, 16:00
54.39
+0.65
(+1.21%)
After-Hours: 20:00
CRISPR Therapeutics Revenue (Quarterly): 200.00M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 200.00M |
| September 30, 2023 | |
| June 30, 2023 | 70.00M |
| March 31, 2023 | 100.00M |
| December 31, 2022 | 0.006M |
| September 30, 2022 | 0.094M |
| June 30, 2022 | 0.158M |
| March 31, 2022 | 0.178M |
| December 31, 2021 | 12.35M |
| September 30, 2021 | 0.329M |
| June 30, 2021 | 900.20M |
| March 31, 2021 | 0.202M |
| December 31, 2020 | 0.194M |
| September 30, 2020 | 0.148M |
| June 30, 2020 | 0.044M |
| March 31, 2020 | 0.157M |
| December 31, 2019 | 77.02M |
| Date | Value |
|---|---|
| September 30, 2019 | 211.93M |
| June 30, 2019 | 0.318M |
| March 31, 2019 | 0.328M |
| December 31, 2018 | 0.115M |
| September 30, 2018 | 0.563M |
| June 30, 2018 | 1.088M |
| March 31, 2018 | 1.358M |
| December 31, 2017 | 32.32M |
| September 30, 2017 | 2.387M |
| June 30, 2017 | 3.582M |
| March 31, 2017 | 2.703M |
| December 31, 2016 | 2.344M |
| September 30, 2016 | 1.549M |
| June 30, 2016 | 0.795M |
| March 31, 2016 | 0.476M |
| December 31, 2015 | 0.247M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.006M
Minimum
Dec 2022
900.20M
Maximum
Jun 2021
87.41M
Average
0.26M
Median
Revenue (Quarterly) Benchmarks
| Vertex Pharmaceuticals Inc | 2.518B |
| Intellia Therapeutics Inc | -1.917M |
| Novartis AG | 11.78B |
| Verve Therapeutics Inc | 5.144M |
| AC Immune SA | 16.70M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 89.35M |
| Total Expenses (Quarterly) | 130.42M |
| EPS Diluted (Quarterly) | 1.13 |
| Enterprise Value | 3.030B |
| Gross Profit Margin (Quarterly) | 90.00% |
| Profit Margin (Quarterly) | 44.67% |
| Earnings Yield | -3.59% |
| Normalized Earnings Yield | -3.591 |